1,581 results on '"Nakanishi, Yoichi"'
Search Results
152. NQO1, MPO, and the risk of lung cancer: A HuGE review
153. Activation of PI3K-Akt pathway mediates antiapoptotic effects of [beta]-adrenergic agonist in airway eosinophils
154. NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration
155. Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis
156. Thioredoxin h regulates calcium dependent protein kinases in plasma membranes
157. Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study: Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category?
158. Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in PC9 Cells
159. Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803)
160. Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405)
161. Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a Large-Scale Nationwide Database
162. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors
163. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: A meta-analysis
164. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells
165. Modern surgical results of lung cancer involving neighboring structures: A retrospective analysis of 531 pT3 cases in a Japanese Lung Cancer Registry Study
166. Genetic Polymorphisms Involved in Carcinogen Metabolism and DNA Repair and Lung Cancer Risk in a Japanese Population
167. IL-6 Induced by Double-Stranded RNA Augments Allergic Inflammation via Suppression of Foxp3+ T-Cell/IL-10 Axis
168. Surgical Outcome of Stage IIIA- cN2/pN2 Non–Small-Cell Lung Cancer Patients in Japanese Lung Cancer Registry Study in 2004
169. Essential Role of B7-H1 in Double-Stranded RNA-Induced Augmentation of an Asthma Phenotype in Mice
170. T Cell Treatment with Small Interfering RNA for Suppressor of Cytokine Signaling 3 Modulates Allergic Airway Responses in a Murine Model of Asthma
171. EGFR Tyrosine Kinase Inhibition Worsens Acute Lung Injury in Mice with Repairing Airway Epithelium
172. Association of Mps one binder kinase activator 1 ( MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
173. Abstract 2412: Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment
174. Abstract 5596: Dynamic monitoring of plasma DAMP proteins during multimodal anticancer treatment in advanced lung cancer patients
175. Abstract 4922: NEUROD1 is highly expressed in extensive small cell lung cancer by promoting migration
176. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration
177. HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
178. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
179. Paired genetic analysis by next‐generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis
180. A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)
181. RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).
182. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
183. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease
184. Inhibition of PI3Kδ Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells
185. Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L)
186. Association between Telomere-Related Polymorphisms and the Risk of IPF and COPD as a Precursor Lesion of Lung Cancer: Findings from the Fukuoka Tobacco-Related Lung Disease (FOLD) Registry
187. Phase I dose‐escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer
188. Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation
189. NEWEST EVIDENCES OF DRUG THERAPY FOR LUNG CANCER: SY 16-03
190. Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study
191. Quantification, Organ-Specific Accumulation and Intracellular Localization of Type II H+-Pyrophosphatase in Arabidopsis thaliana
192. Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408
193. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy
194. Incidence of hypertrophic pulmonary osteoarthropathy associated with primary lung cancer
195. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
196. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab‐Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non‐Small Cell Lung Cancer
197. Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer
198. Involvement of GPx4-Regulated Lipid Peroxidation in Idiopathic Pulmonary Fibrosis Pathogenesis
199. Development of Systemic Musculoarticular Sarcoidosis 30 Years After Onset of Cutaneous Sarcoidosis
200. Current progress and issues of cancer genomic medicine in Kyushu University Hospital
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.